Sep 25, 2026
FDA clears DreaMed Diabetes MODI app for insulin dosing in type 2 diabetes
The FDA has granted 510(k) clearance for MODI, a mobile app from Israeli company DreaMed Diabetes that uses continuous glucose monitoring data to automatically optimize insulin dosing recommendations for adults with type 2 diabetes. This is the first insulin titration algorithm cleared for this patient population.
5 sources
00